DIANA

• Kraj:Polska
• : Język.:polski
• : Utworzony.: 30-12-17
• : Ostatnie Logowanie.: 16-03-22

×

: Kontakt.

: Imię.

: E-mail.

: Wiadomość.

Proszę zamienić znaczniki %d na własne liczby

: Dodaj.

Wiadomość nie może być pusta!

Wiadomość zostanie przetłumaczona po wysłaniu (jeżeli środki są wystarczające)

: Captcha. Kod Ochronny.

Załączniki:

: Wybierz: : Edycja. : Usuń.

: Wybierz: : Edycja. : Usuń.

: Wybierz: : Edycja. : Usuń.

: Wybierz: : Edycja. : Usuń.

: Wybierz: : Edycja. : Usuń.

Ilość dopuszczalnych plików: 5

JPEG, JPG, PNG, GIF, DOC, PDF, ZIP, RAR, TAR, HTML, SWF, TXT, XLS, DOCX, XLSX : lub : ODT : tylko formaty:.

: Maksymalny rozmiar pliku. 3MB.

: Wyślij Wiadomość.

публично-частно партньорство, Apeiron, SRI International, Iktos, антивирусни лекарства, covid-19, коронавирус, ваксина:

: Opis.: BioNTech, модерна, curevac, covid-19, коронавирус, ваксина: 20200320AD BTM Innovations, публично-частно партньорство, Apeiron, SRI International, Iktos, антивирусни лекарства, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi, През 16 март Европейската комисия обяви, че предлага 80 милиона евро за подкрепа на немската компания CureVac за ускоряване на работата по коронавирусната ваксина. Тази информация се появява в деня, след като германските правителствени източници заявиха, че администрацията на Доналд Тръмп търси начин да получи достъп до тази потенциална ваксина. Означава ли това, че има само една компания, която работи върху решение, което е толкова важно за човечеството? СЗО (Световната здравна организация) публикува данни за 13 такива компании на своите уебсайтове, а глобалната база данни показва 30 институции, работещи по тази тема. Има ли шансове за бързо отстраняване на проблемите ни? Дяволът винаги е в детайлите. Официално има само една компания - American Moderna, която премина през клинична фаза на изпитване, при която ваксината се тества при хора. Тестовете се провеждат в Съединените щати във Вашингтонския институт за здравни изследвания в Сиатъл. Такова бързо развитие на потенциална ваксина е безпрецедентно и е възможно, тъй като учените биха могли да използват опита с коронавирусите, предизвикали епидемията от ТОРС и МЕРС. Въпреки рекордната работа, дори ако ваксината се окаже безопасна и ефективна срещу вируса, тя няма да бъде налична поне една година. Всички останали играчи, които искат да разработят коронавирусна ваксина, в момента са в най-напредналия предклиничен етап. Предклиничният етап е изследване в лаборатории и животни, което може да доведе до ваксинация само за около година и половина. Трудно е да се каже кой печели състезанието за ваксината, но най-големите шансове са не стартиращи фирми, а големи фармацевтични компании. Немската компания CureVac си сътрудничи с публична институция със седалище в Осло, т.нар Коалиция за подготвеност за епидемия (CEPI). Те работят върху ваксина на базата на мРНК. Подобно на американската гигантска тРНК Moderna, CureVac иска да докаже, че мРНК ваксините ще бъдат разработени и произведени по-бързо от традиционните ваксини и възнамерява да премине към клинични изпитвания от фаза I в началото на това лято. Подобно на CureVac - немската компания BioNTech, която разработва мРНК ваксини срещу рак и грип - е обект на потенциално партньорство с фармацевтичния гигант Pfizer за разработване на ваксина срещу вируса Covid19. Sanofi и Janssen си сътрудничат с Американския биомедицински разширен офис за изследвания и развитие (BARDA) и също са на предклиничен етап. В процес на изпълнение са и много по-малки проекти. В понеделник2 суми субсидии по програмата Horizon2020 бяха отпуснати на датския публично-частен консорциум: биотехнологични компании ExpreS2ion Biotechnologies и AdaptVac. Консорциумът възнамерява да започне клинично изпитване на фаза I / IIa за ваксината в рамките на 12 месеца. Докато най-ранните ваксини могат да бъдат в предклинична фаза до лятото, регулаторите вероятно ще се нуждаят от една до две години на човешки тестове, за да гарантират, че ваксината е безопасна и ефективна. След получаване на одобрение, компаниите могат да започнат да произвеждат и разпространяват ваксината в търговски мащаб, което също отнема много време. В обобщение светът вижда одобрената ваксина срещу Covid-19 едва около средата на 2121 година. Оказва се обаче, че ваксината не е единственото спасение. Много компании очакват да разработят нови антивирусни лекарства или да адаптират настоящите експериментални лекарства за борба с новия вирус. Това е трудна задача, защото за разлика от бактериите, вирусите се крият в нашите собствени клетки. Това означава, че лекарствата, които спират вируса, засягат по-често нашите клетки, което може да причини странични ефекти. Парижката компания Iktos, занимаваща се с производство на наркотици чрез изкуствен интелект, започна сътрудничество с американската химическа компания SRI International. Целта на сътрудничеството е разработването на нови антивирусни лекарства за лечение на Covid19 и други видове вируси. Австрийската компания за биотехнологии Apeiron започна във фаза II пилотно клинично изпитване на лекарство-кандидат срещу Covid-19 в края на февруари. Протеиновото лекарство вече е завършило фази I и II проучвания при лечението на остро увреждане на белите дробове и се очаква да действа като имитира протеина, с който коронавирусът се свързва по време на белодробна инвазия. също има много проекти, насочени към промяна на използването на одобрени антивирусни лекарства при лечението на Covid-19. Това има предимството, че безопасността на лекарството вече е известна и може да достигне до пазара по-бързо. Изследователи от Гьотинген и Берлин, Германия, в момента изследват потенциала на камостат мезилат - лекарство, одобрено в Япония за лечение на панкреатит. http: //www.e-manus.pl/ BioNTech, moderna, curevac, covid-19, coronavirus, vaccine: 20200320AD BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,  On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details. Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year. All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies. The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer. Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage. Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months. While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021. However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects. The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis. http://www.e-manus.pl/

: Data Publikacji.: 26-11-25

Inovacije, javno-privatno partnerstvo, Apeiron, SRI International, Iktos, antivirusni lekovi, AdaptVac, biotehnologije, pfizer, janssen, sanofi,

: Opis.: BioNTech, moderna, curevac, covid-19, koronavirus, vakcina: 20200320AD BTM Inovacije, javno-privatno partnerstvo, Apeiron, SRI International, Iktos, antivirusni lekovi, AdaptVac, ExpreS2ion biotehnologije, pfizer, janssen, sanofi, Europska komisija je 16. marta objavila da je ponudila 80 milijuna eura za podršku njemačkoj kompaniji CureVac za ubrzavanje rada na vakcini protiv koronavirusa. Te se informacije pojavljuju dan nakon što su njemački vladini izvori rekli da je administracija Donalda Trumpa tražila način da se dobije pristup ovoj potencijalnoj cjepivi. Da li to znači da postoji samo jedna kompanija koja radi na rješenju koje je toliko važno za čovječanstvo? WHO (Svjetska zdravstvena organizacija) na svojim web stranicama objavljuje podatke o 13 takvih kompanija, a baza podataka Global Data ukazuje na 30 institucija koje rade na ovoj temi. Dakle, postoje li šanse za brzi lijek za naše probleme? Đavo je uvijek u detaljima. Službeno, postoji samo jedna kompanija - američka Moderna - koja je prošla fazu kliničkog ispitivanja gdje se cjepivo testira na ljudima. Testovi se provode u Sjedinjenim Američkim Državama na Washingtonskom institutu za zdravstvena istraživanja u Seattlu. Ovakav brzi razvoj potencijalne vakcine bez presedana je i bio moguć jer su naučnici mogli iskoristiti iskustvo s koronavirusima koji su izazvali epidemiju SARS-a i MERS-a. Unatoč rekordnom radu, čak i ako se cjepivo pokaže sigurnim i efikasnim protiv virusa, neće biti na raspolaganju najmanje godinu dana. Svi ostali igrači koji žele razviti vakcinu protiv coronavirusa trenutno su u najnaprednijoj pretkliničkoj fazi. Predklinička faza je istraživanje u laboratorijama i životinjama koje mogu dovesti samo do cijepljenja za oko godinu i pol dana. Teško je reći tko pobjeđuje u utrci za cjepivo, ali najveće šanse nisu startapovi, već velike farmaceutske kompanije. Njemačka tvrtka CureVac surađuje s javnom institucijom sa sjedištem u Oslu, tzv Koalicija za pripravnost za epidemiju (CEPI). Rade na vakcini na bazi mRNA. Poput američke gigante Moderne mRNA, CureVac želi dokazati da će se mRNA cjepiva razviti i proizvesti brže od tradicionalnih cjepiva, te namjerava početkom ovog ljeta krenuti u klinička ispitivanja faze I. Poput CureVac-a, njemačka kompanija BioNTech, koja razvija mRNA cjepiva protiv raka i gripe, predmet je potencijalnog partnerstva s farmaceutskim gigantom Pfizer-om radi razvoja cjepiva protiv virusa Covid19. Sanofi i Janssen surađuju s Američkim naprednim uredom za istraživanje i razvoj biomedicinske medicine (BARDA), a također su u pretkliničkoj fazi. U toku su i mnogi manji projekti. U ponedjeljak je danskom javno-privatnom konzorcijumu dodijeljeno 7 milijuna eura subvencija u okviru programa Horizon2020: biotehnološke kompanije ExpreS2ion Biotechnologies i AdaptVac. Konzorcijum namerava da pokrene kliničko ispitivanje faze I / IIa za vakcinu u roku od 12 meseci. Iako će najstarija cjepiva biti u pretkliničkoj fazi do ljeta, regulatorima će vjerojatno trebati jedna do dvije godine testiranja na ljudima kako bi osigurali da je cjepivo sigurno i efikasno. Nakon dobivanja odobrenja, kompanije mogu započeti proizvodnju i distribuciju cjepiva u komercijalnom obimu, što takođe traje dugo vremena. Ukratko, svijet vidi odobrenu vakcinu protiv Covid-19 tek oko sredine 2121. godine. Međutim, ispostavilo se da vakcina nije jedini spas. Mnoge kompanije očekuju da će razviti nove antivirusne lijekove ili prilagoditi trenutne eksperimentalne lijekove za borbu protiv novog virusa. To je težak zadatak, jer se za razliku od bakterija virusi skrivaju u našim vlastitim ćelijama. To znači da lijekovi koji zaustavljaju virus češće utječu na naše stanice, što može izazvati nuspojave. Pariska kompanija Iktos koja se bavi proizvodnjom lijekova umjetnom inteligencijom započela je suradnju s američkom hemijskom kompanijom SRI International. Cilj suradnje je razviti nove antivirusne lijekove za liječenje Covid19 i drugih vrsta virusa. Austrijska biotehnološka kompanija Apeiron započela je krajem februara pilot-kliničko ispitivanje lijeka kandidata protiv Covid-19. Proteinski lijek je već završio studije faze I i II u liječenju akutnih ozljeda pluća i očekuje se da djeluju oponašajući protein s kojim se koronavirus veže za vrijeme invazije na pluća. postoji i mnogo projekata usmjerenih na promjenu upotrebe odobrenih antivirusnih lijekova u liječenju Covid-19. To ima prednost što je sigurnost lijeka već poznata i može brže stići na tržište. Istraživači iz Göttingena i Berlina u Njemačkoj trenutno istražuju potencijal kamostat mezilata - lijeka koji je u Japanu odobren za liječenje pankreatitisa. http: //www.e-manus.pl/ BioNTech, moderna, curevac, covid-19, coronavirus, vaccine: 20200320AD BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,  On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details. Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year. All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies. The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer. Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage. Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months. While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021. However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects. The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis. http://www.e-manus.pl/

: Data Publikacji.: 26-11-25

дзяржаўна-прыватнае партнёрства, Apeiron, Iktos, супрацьвірусныя прэпараты BioNTech, moderna, curevac, covid-19, коронавірус, вакцына:

: Opis.: BioNTech, moderna, curevac, covid-19, коронавірус, вакцына: 20200320AD BTM Innovations, дзяржаўна-прыватнае партнёрства, Apeiron, SRI International, Iktos, супрацьвірусныя прэпараты, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi, У сакавіку 16 сакавіка Еўракамісія абвясціла, што прапанавала 80 мільёнаў еўра на падтрымку нямецкай кампаніі CureVac для паскарэння працы над коронавіруснай вакцынай. Гэтая інфармацыя з'яўляецца на наступны дзень пасля таго, як нямецкія ўрадавыя крыніцы заявілі, што адміністрацыя Дональда Трампа шукае спосаб атрымаць доступ да гэтай патэнцыяльнай вакцыны. Ці азначае гэта, што ёсць толькі адна кампанія, якая працуе над такім важным для чалавецтва рашэннем? СААЗ (Сусветная арганізацыя аховы здароўя) публікуе дадзеныя пра 13 такіх кампаній на сваіх сайтах, а база дадзеных Global Data паказвае на 30 устаноў, якія працуюць над гэтай тэмай. Ці ёсць шанцы на хуткае ўрэгуляванне нашых праблем? Д'ябал заўсёды ў дэталях. Афіцыйна існуе толькі адна кампанія - American Moderna, якая прайшла этап клінічнага выпрабавання, дзе вакцына выпрабоўваецца на людзях. Тэсты праводзяцца ў ЗША ў Вашынгтонскім інстытуце даследаванняў здароўя ў Сіэтле. Такое хуткае развіццё патэнцыяльнай вакцыны беспрэцэдэнтна і стала магчымым, таму што навукоўцы маглі выкарыстаць вопыт коронавірусаў, якія выклікалі эпідэмію ВРВІ і MERS. Нягледзячы на рэкордныя працы, нават калі вакцына апынецца бяспечнай і эфектыўнай супраць віруса, яна не будзе даступная як мінімум год. Усе астатнія гульцы, якія хочуць распрацаваць вакцыну супраць коронавируса, знаходзяцца на самай перадавой даклінічнай стадыі. Даклінічны этап - гэта даследаванні ў лабараторыях і на жывёл, якія могуць прывесці да вакцынацыі прыблізна праз паўтара года. Цяжка сказаць, хто выйграе гонку за вакцыну, але самыя вялікія шанцы маюць не стартапы, а буйныя фармацэўтычныя кампаніі. Нямецкая кампанія CureVac супрацоўнічае з дзяржаўнай установай, якая базуецца ў Осла, т.зв. Кааліцыя па падрыхтоўцы да эпідэміі (CEPI). Яны працуюць над вакцынай на аснове мРНК. Як і амерыканскі гіганцкі мРНК Moderna, CureVac хоча даказаць, што мРНК вакцыны будуць распрацаваны і выраблены хутчэй, чым традыцыйныя вакцыны, і мае намер перайсці на I этап клінічных выпрабаванняў у пачатку гэтага лета. Як і CureVac - нямецкая кампанія BioNTech, якая займаецца распрацоўкай вакцын мРНК супраць раку і грыпу - з'яўляецца прадметам патэнцыяльнага партнёрства з фармацэўтычным гігантам Pfizer па распрацоўцы вакцыны супраць віруса Covid19. Санофі і Янсэн супрацоўнічаюць з Амерыканскім прасунутым біямедыцынскім бюро па даследаваннях і распрацоўках (BARDA), а таксама знаходзяцца на даклінічнай стадыі. Шмат меншых праектаў таксама вядзецца. У панядзелак2 7 мільёнаў еўра субсідый у рамках праграмы Horizon2020 былі выдзелены дацкаму дзяржаўна-прыватнаму кансорцыуму: біятэхналагічным кампаніям ExpreS2ion Biotechnologies і AdaptVac. Кансорцыум мае намер запусціць клінічнае выпрабаванне вакцыны фазы I / IIa на працягу 12 месяцаў. Хоць самыя раннія вакцыны могуць знаходзіцца ў даклінічнай фазе да лета, рэгулятары, верагодна, спатрэбяцца ад аднаго да двух гадоў тэставання на чалавеку, каб гарантаваць, што вакцына бяспечная і эфектыўная. Пасля атрымання дазволу кампаніі могуць пачаць вырабляць і распаўсюджваць вакцыну ў камерцыйных маштабах, што таксама займае шмат часу. Такім чынам, свет бачыць ухваленую вакцыну Covid-19 толькі прыблізна ў сярэдзіне 2121 года. Аднак аказваецца, што вакцына - не адзінае выратаванне. Многія кампаніі разлічваюць распрацаваць новыя супрацьвірусныя прэпараты альбо адаптаваць сучасныя эксперыментальныя лекі для барацьбы з новым вірусам. Гэта складаная задача, таму што, у адрозненне ад бактэрый, вірусы хаваюцца ў нашых уласных клетках. Гэта азначае, што лекі, якія спыняюць вірус, часцей дзівяць нашы клеткі, што можа выклікаць пабочныя эфекты. Парыжская кампанія Iktos, якая займаецца вытворчасцю лекаў пры дапамозе штучнага інтэлекту, пачала супрацоўніцтва з амерыканскай хімічнай кампаніяй SRI International. Мэта супрацоўніцтва складаецца ў распрацоўцы новых супрацьвірусных прэпаратаў для лячэння Covid19 і іншых відаў вірусаў. У канцы лютага аўстрыйская біятэхналагічная кампанія Apeiron распачала фазу II пілотнага клінічнага выпрабавання прэпарата-кандыдата супраць Covid-19. Бялковы прэпарат ужо завяршыў даследаванні фазы I і II у лячэнні вострай траўмы лёгкіх і, як чакаецца, дзейнічае, імітуючы бялок, з якім каранавірус звязваецца падчас лёгачнай інвазіі. Таксама існуе мноства праектаў, накіраваных на змяненне выкарыстання дазволеных супрацьвірусных прэпаратаў пры лячэнні Covid-19. Гэта мае перавагу ў тым, што бяспека лекі ўжо вядомая і можа выйсці на рынак хутчэй. Даследчыкі з Гётынгена і Берліна, Германія, у цяперашні час даследуюць патэнцыял камостата мезилата - прэпарата, дазволенага ў Японіі для лячэння панкрэатыту. http: //www.e-manus.pl/ BioNTech, moderna, curevac, covid-19, coronavirus, vaccine: 20200320AD BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,  On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details. Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year. All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies. The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer. Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage. Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months. While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021. However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects. The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis. http://www.e-manus.pl/

: Data Publikacji.: 26-11-25

বায়োএনটেক, মডেরেনা, কুরিভ্যাক, কোভিড -১৯, করোনভাইরাস, ভ্যাকসিন:

: Opis.: বায়োএনটেক, মডেরেনা, কুরিভ্যাক, কোভিড -১৯, করোনভাইরাস, ভ্যাকসিন: 20200320AD বিটিএম ইনোভেশনস, পাবলিক-প্রাইভেট পার্টনারশিপ, অ্যাপিওরন, এসআরআই ইন্টারন্যাশনাল, ইক্টোস, অ্যান্টিভাইরাল ড্রাগস, অ্যাডাপ্টভ্যাক, এক্সপ্রেস 2 জৈব প্রযুক্তি, ফাইজার, জ্যানসেন, সানোফি, ১ March ই মার্চ, ইউরোপীয় কমিশন ঘোষণা করেছিল যে করোনোভাইরাস ভ্যাকসিনের কাজকে ত্বরান্বিত করতে জার্মান সংস্থা কুরিভ্যাককে সহায়তা দেওয়ার জন্য ৮০ মিলিয়ন ইউরো সরবরাহ করেছে। জার্মান সরকার সূত্র জানিয়েছে যে ডোনাল্ড ট্রাম্প প্রশাসন এই সম্ভাব্য ভ্যাকসিনের অ্যাক্সেস পাওয়ার উপায় খুঁজছে। এর অর্থ কি এই যে কেবলমাত্র একটি সংস্থাই এমন একটি সমাধান নিয়ে কাজ করছে যা মানবতার পক্ষে এত গুরুত্বপূর্ণ? ডাব্লুএইচও (ওয়ার্ল্ড হেলথ অর্গানাইজেশন) এর ওয়েবসাইটে ১৩ টি সংস্থার ডেটা প্রকাশ করে এবং গ্লোবাল ডেটা ডাটাবেস এই বিষয়টিতে কাজ করা 30 টি প্রতিষ্ঠানকে নির্দেশ করে। তাহলে কি আমাদের সমস্যাগুলির দ্রুত প্রতিকারের কোনও সম্ভাবনা রয়েছে? শয়তান সর্বদা বিশদে থাকে। আনুষ্ঠানিকভাবে, কেবলমাত্র একটি সংস্থা রয়েছে - আমেরিকান মোদার্না - এটি একটি ক্লিনিকাল ট্রায়াল পর্ব পেরিয়ে গেছে যেখানে মানুষের মধ্যে ভ্যাকসিন পরীক্ষা করা হচ্ছে। সিয়াটেলের ওয়াশিংটন ইনস্টিটিউট অফ হেলথ রিসার্চ-এ যুক্তরাষ্ট্রে পরীক্ষা করা হয়। একটি সম্ভাব্য ভ্যাকসিনের এ জাতীয় দ্রুত বিকাশ নজিরবিহীন এবং এটি সম্ভব হয়েছিল কারণ বিজ্ঞানীরা করোনভাইরাসগুলির সাথে অভিজ্ঞতাটি সারস এবং এমআরএস মহামারীর কারণ হিসাবে ব্যবহার করতে পারেন। রেকর্ড ব্রেকিং কাজ সত্ত্বেও, ভ্যাকসিনটি ভাইরাসের বিরুদ্ধে নিরাপদ এবং কার্যকর প্রমাণিত হলেও, এটি কমপক্ষে এক বছরের জন্য উপলব্ধ হবে না। অন্য যে সমস্ত খেলোয়াড় একটি করোনভাইরাস ভ্যাকসিন বিকাশ করতে চান তারা বর্তমানে সবচেয়ে উন্নত প্রাক-প্রকৃতির পর্যায়ে রয়েছে। প্রকৃত পর্যায়টি ল্যাবরেটরি এবং প্রাণীদের গবেষণা যা প্রায় দেড় বছরের মধ্যে কেবল টিকা দিতে পারে। ভ্যাকসিনের প্রতিযোগিতা কে জিতবে তা বলা শক্ত, তবে সবচেয়ে বড় সম্ভাবনা স্টার্ট-আপগুলি নয়, বড় ওষুধ সংস্থাগুলি। জার্মান সংস্থা কুরেভ্যাক তথাকথিত অসলো ভিত্তিক একটি সরকারী প্রতিষ্ঠানের সাথে সহযোগিতা করে মহামারী প্রস্তুতি জন্য কোয়ালিশন (সিইপিআই)। তারা এমআরএনএ ভিত্তিক ভ্যাকসিন নিয়ে কাজ করছে। আমেরিকান জায়ান্ট মডেরেনা এমআরএনএ-র মতো কুরিভ্যাক প্রমাণ করতে চায় যে এমআরএনএ ভ্যাকসিনগুলি গতানুগতিক ভ্যাকসিনগুলির চেয়ে দ্রুত তৈরি এবং প্রস্তুত করা হবে এবং এই গ্রীষ্মের প্রথম দিকে প্রথম পর্যায়ের ক্লিনিকাল ট্রায়ালগুলিতে যাওয়ার ইচ্ছা রয়েছে। কুরিভ্যাকের মতো - জার্মান সংস্থা বায়োএনটেক, যা ক্যান্সার এবং ইনফ্লুয়েঞ্জার জন্য এমআরএনএ ভ্যাকসিন তৈরি করে - ওষুধ জায়ান্ট ফাইজারের সাথে কোভিড ১৯ ভাইরাসের বিরুদ্ধে একটি ভ্যাকসিন তৈরির সম্ভাব্য অংশীদারিত্বের বিষয়। সানোফি এবং জানসেন আমেরিকান বায়োমেডিকাল অ্যাডভান্সড অফিস ফর রিসার্চ অ্যান্ড ডেভেলপমেন্টের (বারদা) সাথে সহযোগিতা করেছেন এবং একটি প্রাক্কলিত পর্যায়েও রয়েছেন। অনেক ছোট প্রকল্পও চলছে। সোমবার2-তে হরিজন 2020 প্রোগ্রামের আওতায় 7 মিলিয়ন ইউএসডি অনুদানের জন্য ডেনিশের পাবলিক-প্রাইভেট কনসোর্টিয়ামকে বরাদ্দ করা হয়েছিল: বায়োটেকনোলজি সংস্থা এক্সপ্রেস 2 বিজন বায়োটেকনোলজিস এবং অ্যাডাপ্টভ্যাক। কনসোর্টিয়ামটি 12 মাসের মধ্যে ভ্যাকসিনের জন্য প্রথম পর্যায় I / IIa ক্লিনিকাল ট্রায়াল চালু করতে চায়। যদিও গ্রীষ্মের মধ্যে প্রথম দিকের ভ্যাকসিনগুলি প্রাক-ক্লিনিকাল পর্যায়ে থাকতে পারে তবে এই ভ্যাকসিনটি নিরাপদ এবং কার্যকর কিনা তা নিশ্চিত করতে নিয়ামকদের সম্ভবত এক থেকে দুই বছরের মানবিক পরীক্ষার প্রয়োজন হবে। অনুমোদনের পরে, সংস্থাগুলি বাণিজ্যিক স্কেলে ভ্যাকসিন উত্পাদন এবং বিতরণ শুরু করতে পারে, এতে দীর্ঘ সময়ও লাগে। সংক্ষেপে, বিশ্ব অনুমোদিত কোভিড -১৯ টি ভ্যাকসিন কেবলমাত্র 2121 সালের মাঝামাঝি সময়ে দেখে। তবে দেখা যাচ্ছে যে ভ্যাকসিনই একমাত্র পরিত্রাণ নয়। অনেক সংস্থা নতুন ভাইরাসের বিরুদ্ধে লড়াই করার জন্য নতুন অ্যান্টিভাইরাল ওষুধ বিকাশ করবে বা বর্তমান পরীক্ষামূলক ওষুধগুলিকে মানিয়ে নেবে বলে আশাবাদী। এটি একটি কঠিন কাজ কারণ ব্যাকটিরিয়াগুলির বিপরীতে ভাইরাসগুলি আমাদের নিজস্ব কোষগুলিতে লুকায়। এর অর্থ হ'ল যে ওষুধগুলি ভাইরাসটি আরও বেশি করে থামায় সেগুলি আমাদের কোষগুলিকে প্রায়শই প্রভাবিত করে, যার ফলে পার্শ্ব প্রতিক্রিয়া হতে পারে। কৃত্রিম বুদ্ধিমত্তার মাধ্যমে ওষুধের উত্পাদন নিয়ে কাজ করা প্যারিসের সংস্থা ইক্টোস আমেরিকান রাসায়নিক সংস্থা এসআরআই ইন্টারন্যাশনালের সাথে সহযোগিতা শুরু করে। সহযোগিতার লক্ষ্য হল কোভিড 19 এবং অন্যান্য ধরণের ভাইরাসের চিকিত্সার জন্য নতুন অ্যান্টিভাইরাল ড্রাগগুলি বিকাশ করা। অস্ট্রিয়ান জৈবপ্রযুক্তি সংস্থা অপিওরন ফেব্রুয়ারির শেষে কোভিড -১৯ এর বিরুদ্ধে প্রার্থী ড্রাগের দ্বিতীয় পর্বের পাইলট ক্লিনিকাল ট্রায়াল শুরু করেছিলেন। প্রোটিন ড্রাগটি তীব্র ফুসফুসের আঘাতের চিকিত্সার জন্য ইতিমধ্যে প্রথম এবং দ্বিতীয় পর্যায়ের অধ্যয়ন সম্পন্ন করেছে এবং ফুসফুসের আক্রমণের সময় যে প্রোটিন দিয়ে করোন ভাইরাস বেঁধেছিল তা নকল করে কাজ করার আশা করা হচ্ছে। কোভিড -19-এর চিকিত্সায় অনুমোদিত অ্যান্টিভাইরাল ওষুধের ব্যবহার পরিবর্তন করার লক্ষ্যেও অনেকগুলি প্রকল্প রয়েছে। এটির সুবিধাটি রয়েছে যে ওষুধের সুরক্ষাটি ইতিমধ্যে জানা গেছে এবং দ্রুত বাজারে পৌঁছতে পারে। জার্মানির গ্যাটিনজেন এবং বার্লিনের গবেষকরা বর্তমানে কমোস্ট্যাট মাইসেলেটের সম্ভাবনাগুলি তদন্ত করছেন - যা অগ্ন্যাশয় রোগের চিকিত্সার জন্য জাপানে অনুমোদিত একটি ওষুধ। http: //www.e-manus.pl/ BioNTech, moderna, curevac, covid-19, coronavirus, vaccine: 20200320AD BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,  On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details. Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year. All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies. The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer. Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage. Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months. While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021. However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects. The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis. http://www.e-manus.pl/

: Data Publikacji.: 26-11-25